Brain-derived neurotrophic factor (BDNF) is a critical neurotrophin that plays essential roles in neuronal survival, development, plasticity, and function throughout the lifespan. BDNF-expressing neurons represent a fundamental component of the nervous system, with widespread distribution across cortical, subcortical, and peripheral regions. These neurons are essential for learning, memory, mood regulation, and the response to neural injury[1][2].
BDNF is the most abundant neurotrophin in the mammalian brain and exerts its effects primarily through the TrkB (tropomyosin receptor kinase B) receptor. The BDNF-TrkB signaling pathway modulates synaptic transmission, dendritic branching, long-term potentiation (LTP), and neurogenesis—all processes central to higher cognitive function and vulnerable in neurodegenerative diseases[3][4].
BDNF neurons are neurons that produce and release brain-derived neurotrophic factor, the most abundant neurotrophin in the brain. These neurons play critical roles in neuronal survival, synaptic plasticity, dendritic branching, and long-term potentiation (LTP). BDNF is essential for cognitive function, memory formation, and neuroprotection throughout the lifespan.
The human BDNF gene (BDNF) is located on chromosome 11p14.1 and contains multiple 5' non-coding exons that are differentially spliced to a common 3' exon encoding the mature protein. This complex structure allows for tissue-specific and activity-dependent regulation through distinct promoter regions. Transcription of BDNF is induced by neuronal activity, calcium influx, and various signaling molecules including cyclic AMP, CREB (cAMP response element-binding protein), and NF-κB[5].
BDNF expression is dynamically regulated throughout development and in adulthood. During embryonic development, BDNF supports neuronal differentiation, migration, and synapse formation. In the adult brain, BDNF expression maintains synaptic plasticity and supports circuit refinement. Activity-dependent regulation allows BDNF to couple neuronal activity with structural and functional plasticity, forming a molecular substrate for learning and memory[6].
BDNF is synthesized as a precursor protein (pre-proBDNF, approximately 32 kDa) that undergoes processing to generate mature BDNF (approximately 14 kDa). This processing occurs through the regulated secretory pathway and involves cleavage by furin in the endoplasmic reticulum and by extracellular proteases including plasmin and matrix metalloproteinases (MMPs) in the synaptic cleft[7].
The balance between proBDNF and mature BDNF is functionally significant. ProBDNF signals through the p75NTR (p75 neurotrophin receptor) and sortilin receptors, often promoting apoptosis, pruning, and synaptic depression. In contrast, mature BDNF binds preferentially to TrkB receptors, supporting survival, growth, and synaptic strengthening. This "yin-yang" relationship between proBDNF and mature BDNF allows for precise regulation of neuronal plasticity[7:1].
BDNF binds to TrkB with high affinity, triggering dimerization and autophosphorylation of tyrosine residues in the intracellular domain. This activates multiple downstream signaling cascades:
PI3K/Akt Pathway: Phosphoinositide 3-kinase (PI3K) activation leads to Akt phosphorylation, promoting cell survival through inhibition of pro-apoptotic proteins including Bad, caspase-9, and GSK-3β.
MAPK/ERK Pathway: Ras/Raf/MEK/ERK signaling promotes neuronal differentiation, dendritic growth, and synaptic plasticity. This pathway is critical for LTP and memory consolidation.
PLC-γ Pathway: Phospholipase C-gamma (PLC-γ) activation increases intracellular calcium through IP3-mediated release from endoplasmic reticulum stores, modulating synaptic transmission and gene transcription.
BDNF-expressing neurons are distributed throughout the central nervous system with highest concentrations in:
Hippocampus: The dentate gyrus granule cells and CA1-CA3 pyramidal neurons show robust BDNF expression. Hippocampal BDNF is essential for spatial memory formation and pattern separation[1:1].
Cerebral Cortex: Layer 2/3 pyramidal neurons in the neocortex express high levels of BDNF. Cortical BDNF supports experience-dependent plasticity and sensory map refinement.
Basal Forebrain: Cholinergic neurons of the nucleus basalis, diagonal band, and medial septum produce BDNF and project to the hippocampus and cortex. This BDNF supports cortical plasticity and memory function.
Striatum: Medium spiny neurons and interneurons in the caudate nucleus and putamen express BDNF, supporting motor learning and habit formation.
Amygdala and Hypothalamus: BDNF in these regions modulates emotional processing, stress responses, and autonomic function.
BDNF is localized to both pre-synaptic and post-synaptic compartments. In pre-synaptic terminals, BDNF is packaged into secretory vesicles and released in an activity-dependent manner. Post-synaptic BDNF localizes to dendritic spines, where it modulates spine morphology and synaptic strength. This bidirectional distribution allows BDNF to coordinate pre-synaptic release with post-synaptic responsiveness.
BDNF is a critical regulator of LTP, the cellular basis for learning and memory. BDNF enhances LTP through multiple mechanisms:
Synaptic Tagging: BDNF facilitates the establishment of synaptic tags that capture the products of gene transcription necessary for long-term memory.
AMPA Receptor Trafficking: BDNF signaling increases the insertion of AMPA receptors into the post-synaptic membrane, strengthening synaptic transmission.
Dendritic Spine Morphogenesis: BDNF promotes the growth and stabilization of dendritic spines, creating structural substrates for enhanced synaptic connectivity[5:1].
During development, BDNF supports the formation and refinement of synaptic connections. BDNF promotes:
Beyond its role in Hebbian plasticity, BDNF participates in homeostatic scaling—a process that adjusts synaptic strength globally in response to prolonged activity changes. BDNF-mediated signaling allows neurons to maintain stable firing rates despite altered input patterns.
Alzheimer's disease (AD) is associated with marked reductions in BDNF expression and signaling. Post-mortem studies reveal decreased BDNF in the hippocampus and cortex of AD patients, correlating with cognitive decline[8][9].
Amyloid-Beta Effects: Amyloid-beta (Aβ) oligomers reduce BDNF expression through interference with NMDA receptor signaling and CREB activation. Aβ also impairs BDNF signaling downstream of TrkB, reducing the neuroprotective effects of BDNF.
Tau Pathology: Hyperphosphorylated tau disrupts BDNF transport along microtubules, reducing BDNF delivery to synapses. Loss of BDNF support may accelerate tau pathology through increased neuronal vulnerability.
Therapeutic Implications: Exercise, cognitive enrichment, and certain pharmacological agents increase BDNF expression and may slow cognitive decline in AD.
BDNF supports the survival and function of dopaminergic neurons in the substantia nigra pars compacta. Loss of BDNF support contributes to the selective vulnerability of these neurons in Parkinson's disease (PD)[8:1][10].
Neuroprotective Strategies: GDNF (glial cell line-derived neurotrophic factor) family members have been tested in PD clinical trials with some evidence of benefit. BDNF and related trophic factors may support remaining dopaminergic neurons and promote functional recovery.
Alpha-Synuclein Interaction: Alpha-synuclein pathology may interfere with BDNF signaling, creating a vicious cycle of trophic support loss and progressive neurodegeneration.
Huntington's disease (HD) is associated with reduced BDNF expression in the cortex and striatum. The mutant huntingtin protein impairs BDNF transcription and transport, contributing to striatal neuron vulnerability[11]. BDNF-enhancing strategies are under investigation for HD treatment.
BDNF can be measured in cerebrospinal fluid (CSF) and blood, making it a candidate biomarker for neurodegenerative diseases. However, the relationship between peripheral and central BDNF levels is complex, and clinical utility remains limited.
Small Molecule Agonists: TrkB agonists that can cross the blood-brain barrier are under development. These compounds aim to bypass the requirement for BDNF delivery by directly activating TrkB signaling.
Gene Therapy: AAV-mediated BDNF delivery has shown promise in animal models but faces challenges including optimal dosing, targeting, and avoiding off-target effects.
Cell-Based Therapy: Stem cell approaches that produce BDNF or provide trophic support are being explored for multiple neurodegenerative conditions.
Exercise and Environmental Enrichment: Voluntary exercise, cognitive stimulation, and environmental enrichment consistently increase BDNF expression and improve cognitive outcomes in both animal models and human studies.
The BDNF Val66Met polymorphism (valine to methionine substitution at codon 66) affects activity-dependent BDNF secretion. Met carriers show reduced BDNF release and have been associated with:
This polymorphism highlights the importance of genetic factors in BDNF biology and may inform personalized therapeutic approaches.
The relative contributions of proBDNF and mature BDNF to neuronal function remain incompletely understood. Developing selective agonists and antagonists for each form will clarify their distinct roles.
The blood-brain barrier limits delivery of therapeutic BDNF. New approaches including intranasal delivery, focused ultrasound, and novel bioengineered proteins may enable effective CNS targeting.
Genetic variants in the BDNF pathway may influence disease progression and treatment response. Stratifying patients based on BDNF-related genotypes could improve therapeutic outcomes.
BDNF and neuroinflammation engage in complex bidirectional communication that significantly impacts neurodegenerative disease progression[8:2]. Microglial cells are both sources of BDNF and targets of BDNF signaling, creating intricate feedback loops that modulate both immune responses and neuronal survival.
Microglial BDNF Production: Activated microglia produce and secrete BDNF in response to inflammatory stimuli. This microglial-derived BDNF can promote neuronal survival under inflammatory conditions, representing a neuroprotective response to CNS injury.
BDNF Effects on Microglia: BDNF signaling modulates microglial activation states. TrkB activation can shift microglia toward an anti-inflammatory (M2-like) phenotype, potentially reducing neurotoxic inflammation. However, the effects are context-dependent and vary with brain region and disease state.
Pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 negatively regulate BDNF expression and secretion. This creates a pathological feed-forward loop where neuroinflammation suppresses BDNF-mediated neuroprotection, accelerating neurodegeneration.
TNF-α: Suppresses BDNF transcription through NF-κB-dependent mechanisms while promoting cleavage of proBDNF to yield the p75NTR-selective fragment.
IL-1β: Interferes with CREB-mediated BDNF transcription and impairs activity-dependent BDNF secretion.
IL-6: Reduces BDNF expression in neurons while paradoxically stimulating BDNF production in astrocytes.
Understanding the BDNF-neuroinflammation axis suggests novel therapeutic approaches:
Anti-inflammatory + BDNF enhancement: Combined strategies that reduce neuroinflammation while boosting BDNF may prove more effective than either approach alone.
Microglial modulation: Targeting microglial BDNF production could promote neuroprotection while reducing harmful inflammation.
Timing considerations: BDNF therapy may be most effective during periods of peak neuroinflammation, when neurotrophic support is most needed.
The hippocampus exhibits the highest BDNF expression in the adult brain, with particularly dense expression in the dentate gyrus and CA regions[1:2]. Hippocampal BDNF is essential for:
Spatial memory formation: BDNF supports long-term potentiation in CA1 and dentate gyrus, critical for encoding spatial information.
Pattern separation: BDNF in dentate granule cells supports the orthogonalization of similar inputs, preventing memory interference.
Adult neurogenesis: BDNF promotes the survival and differentiation of new neurons in the subgranular zone.
Contextual fear conditioning: BDNF is required for the consolidation of contextual fear memories.
Cortical BDNF supports:
Experience-dependent plasticity: Visual cortex BDNF levels regulate critical period timing for sensory development.
Motor learning: Motor cortex BDNF supports skill acquisition and motor training-induced structural plasticity.
Executive function: Prefrontal cortex BDNF is implicated in working memory and cognitive flexibility.
Cerebellar BDNF plays roles in:
Motor coordination: Purkinje cell BDNF supports cerebellar-dependent motor learning.
Balance and gait: Cerebellar BDNF contributes to vestibular function and proprioceptive processing.
Small molecule TrkB agonists: Several TrkB-selective agonists have entered clinical development, including:
PDE inhibitors: Phosphodiesterase inhibitors that increase cAMP and indirectly enhance BDNF expression:
GABA receptor modulators: Compounds that reduce excitotoxicity while promoting BDNF expression.
AAV-mediated delivery: Adeno-associated viral vectors encoding BDNF have shown promise in animal models[@ramachandran2021]:
Non-viral approaches: Polymer nanoparticles and exosomes are being explored as safer alternatives to viral delivery.
Stem cell approaches: Mesenchymal stem cells (MSCs) and neural stem cells (NSCs) can be engineered to secrete BDNF:
Encapsulated cell therapy: Genetically engineered cells encapsulated in semipermeable membranes allow BDNF release while protecting cells from immune rejection.
Exercise: Voluntary exercise is the most robust non-pharmacological method to increase BDNF:
Dietary interventions: Several dietary approaches modulate BDNF:
Cognitive training: Learning itself increases BDNF, suggesting cognitive enrichment as a therapeutic strategy.
CSF BDNF: Cerebrospinal fluid BDNF reflects central nervous system levels:
Serum BDNF: Peripheral measurements are more accessible:
Brain imaging: PET ligands for TrkB are under development to visualize BDNF signaling in vivo.
Diagnostic markers: BDNF levels show promise as:
Prognostic value: Low BDNF predicts:
BDNF is reduced in the striatum and cerebellum in MSA:
Reduced cortical and subcortical BDNF:
Altered BDNF signaling in FTD:
Numakawa T, Odaka H, Adachi N. Brain-derived neurotrophic factor and Alzheimer's disease: Pathophysiological mechanism and therapeutic potential. International Journal of Molecular Sciences. 2021. ↩︎ ↩︎ ↩︎
Kowiański P, Lietzau G, Czuba E, Waśkow M, Steliga A, Moryś J. BDNF: A key factor with multipotent impact on brain signaling and synaptic plasticity. Cellular and Molecular Neurobiology. 2021. ↩︎
Pang PT, Lu B. Regulation of synaptic plasticity by brain-derived neurotrophic factor. Biochemical Society Transactions. 2004. ↩︎
Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic plasticity as a candidate mechanism for antidepressant action. Nature Reviews Neuroscience. 2013. ↩︎
Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: A key molecule for memory in the healthy and the pathological brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022. ↩︎ ↩︎
Gomez LM, Valero J, Aguilera Y, et al. Neurotrophin-3 promotes functional recovery after spinal cord injury. Nature Medicine. 2024. ↩︎
Cheng J, Xiong Z, Dougherty Y, et al. A proBDNF fragment is a potential therapeutic target for neurological disorders. Nature Reviews Drug Discovery. 2012. ↩︎ ↩︎
Zucchelli S, Maragakis M. Brain-derived neurotrophic factor in neurodegeneration. Biomedicines. 2019. ↩︎ ↩︎ ↩︎
Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature BDNF are decreased in the prefrontal cortex of brains from patients with Alzheimer's disease. Journal of Neuropathology and Experimental Neurology. 2005. ↩︎
Mogi M, Togari A, Kondo T, et al. Brain-derived neurotrophic factor concentration in the cerebrospinal fluid of patients with Parkinson's disease. Neuroscience Letters. 1999. ↩︎
Zuccato C, Tartari M, Crotti A, et al. Huntingtin dysfunction causes BDNF reduction in neurons. Nature Genetics. 2008. ↩︎